The scientific community is closely watching trajectory of Trontinemab, a experimental treatment showing remarkable results in early clinical assessments. Trontinemab targets aggregated tau protein, a key hallmark of Alzheimer’s , believed to be more linked to cognitive impairment than the amyloid plaques that previously received greater focus .